Evidence map›Paper›PMID 29467412›Full record

ArticleCell death & disease2018

IL-32 gamma reduces lung tumor development through upregulation of TIMP-3 overexpression and hypomethylation.

Jaesuk Yun, Mi Hee Park, Dong Ju Son, Kyung Tak Nam, Dae Bong Moon, Jung Heun Ju, Ok Kyung Hwang, Jeong Soon Choi, Tae Hoon Kim, Young Suk Jung and 4 more

Open access · goldAbstract read
In one paragraph

Article in Cell death & disease, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Jaesuk YunCollege of Pharmacy and Medical Research Center, Chungbuk National University, Osongsaengmyeong1-ro 194-21, Heungduk-gu, Cheongju, Chungbuk, 28160, Republic of Korea.
Mi Hee ParkCollege of Pharmacy and Medical Research Center, Chungbuk National University, Osongsaengmyeong1-ro 194-21, Heungduk-gu, Cheongju, Chungbuk, 28160, Republic of Korea.
Dong Ju SonCollege of Pharmacy and Medical Research Center, Chungbuk National University, Osongsaengmyeong1-ro 194-21, Heungduk-gu, Cheongju, Chungbuk, 28160, Republic of Korea.
Kyung Tak NamCollege of Pharmacy and Medical Research Center, Chungbuk National University, Osongsaengmyeong1-ro 194-21, Heungduk-gu, Cheongju, Chungbuk, 28160, Republic of Korea.
Dae Bong MoonCollege of Pharmacy and Medical Research Center, Chungbuk National University, Osongsaengmyeong1-ro 194-21, Heungduk-gu, Cheongju, Chungbuk, 28160, Republic of Korea.
Jung Heun JuCollege of Pharmacy and Medical Research Center, Chungbuk National University, Osongsaengmyeong1-ro 194-21, Heungduk-gu, Cheongju, Chungbuk, 28160, Republic of Korea.
Ok Kyung HwangCollege of Pharmacy and Medical Research Center, Chungbuk National University, Osongsaengmyeong1-ro 194-21, Heungduk-gu, Cheongju, Chungbuk, 28160, Republic of Korea.
Jeong Soon ChoiCollege of Pharmacy and Medical Research Center, Chungbuk National University, Osongsaengmyeong1-ro 194-21, Heungduk-gu, Cheongju, Chungbuk, 28160, Republic of Korea.
Tae Hoon KimCollege of Pharmacy and Medical Research Center, Chungbuk National University, Osongsaengmyeong1-ro 194-21, Heungduk-gu, Cheongju, Chungbuk, 28160, Republic of Korea.
Young Suk JungCollege of Pharmacy and Medical Research Center, Chungbuk National University, Osongsaengmyeong1-ro 194-21, Heungduk-gu, Cheongju, Chungbuk, 28160, Republic of Korea.
Dae Yeon HwangDepartment of Biomaterial Science, Pusan National University, Miryang, Kyungnam, 50463, Republic of Korea.
Sang Bae HanCollege of Pharmacy and Medical Research Center, Chungbuk National University, Osongsaengmyeong1-ro 194-21, Heungduk-gu, Cheongju, Chungbuk, 28160, Republic of Korea.ORCID 0000-0001-6656-6523
Do-Young YoonDepartment of Bioscience and Biotechnology, Bio/Molecular Informatics Center, Konkuk University, Gwangjin-gu, Seoul, 05029, Republic of Korea. ydy4218@konkuk.ac.kr.
Jin Tae HongCollege of Pharmacy and Medical Research Center, Chungbuk National University, Osongsaengmyeong1-ro 194-21, Heungduk-gu, Cheongju, Chungbuk, 28160, Republic of Korea. jinthong@chungbuk.ac.kr.
Chungbuk National University · KRKonkuk University · KRPusan National University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The low expression of tissue inhibitor of metalloproteinase 3 (TIMP-3) is important in inflammatory responses. Therefore, inhibition of TIMP-3 may promote tumor development. Our study showed that expression of TIMP-3 was elevated in lL-32γ mice lung tissues. In this study, we investigated whether IL-32γ mice inhibited lung tumor development through overexpression of TIMP-3 and its methylation. To explore the possible underlying mechanism, lung cancer cells were transfected with IL-32γ cDNA plasmid. A marked increase in TIMP-3 expression was caused by promoter methylation. Mechanistic studies indicated that TIMP-3 overexpression reduced NF-κB activity, which led to cell growth inhibition in IL-32γ transfected lung cancer cells. We also showed that IL-32γ inhibits expression of DNA (cytosine-5-)-methyltransferase 1 (DNMT1). Moreover, IL-32γ inhibits the binding of DNMT1 to TIMP-3 promoter, but this effect was reversed by the treatment of DNA methyltransferase inhibitor (5-Aza-CdR) and NF-κB inhibitor (PS1145), suggesting that a marked increase in TIMP-3 expression was caused by inhibition of promoter hypermethylation via decreased DNMT1 expression through the NF-κB pathway. In an in vivo carcinogen induced lung tumor model, tumor growth was inhibited in IL-32γ overexpressed mice with elevated TIMP-3 expression and hypomethylation accompanied with reduced NF-κB activity. Moreover, in the lung cancer patient tissue, the expression of IL-32 and TIMP-3 was dramatically decreased at a grade-dependent manner compared to normal lung tissue. In summary, IL-32γ may increase TIMP-3 expression via hypomethylation through inactivation of NF-κB activity, and thereby reduce lung tumor growth.

Indexed as

AnimalsApoptosisCarcinogenesisCell Line, TumorCell ProliferationCell SurvivalDNA (Cytosine-5-)-Methyltransferase 1DNA MethylationGene Expression Regulation, NeoplasticHumansInterleukinsLung NeoplasmsMice, Inbred C57BLNeoplasm MetastasisNF-kappa BPromoter Regions, GeneticDNA (Cytosine-5-)-Methyltransferase 1DNMT1 protein, humanIL32 protein, humanInterleukinsNF-kappa BTIMP3 protein, humanTissue Inhibitor of Metalloproteinase-3

Identifiers

PMID29467412
PMCPMC5833366
OpenAlexW2790013220

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.